Seminars in Cancer Biology

Article	Citations
Ferroptosis is a type of autophagy-dependent cell death	546
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	258
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges	224
The role of SOX family members in solid tumours and metastasis	208
Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy	194
Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins	178
Emerging roles of ECM remodeling processes in cancer	177
SOX2 in development and cancer biology	175
Radiomics in breast cancer classification and prediction	170
Targeting p53 for the treatment of cancer	167
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond	160
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression	157
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	153
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics	151
Risk of colorectal cancer in inflammatory bowel diseases	142
Immune checkpoints in the tumor microenvironment	134
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review	133
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	133
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives	131
An update on vitamin D signaling and cancer	130
Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art	126
Machine and deep learning approaches for cancer drug repurposing	123
lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions	121
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects	121
RAF-MEK-ERK pathway in cancer evolution and treatment	119

Revisiting the hallmarks of cancer: The role of hyaluronan	119
Regulation of autophagy by canonical and non-canonical ER stress responses	118
Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers	117
Pathology of triple negative breast cancer	115
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies	113
SOX4: The unappreciated oncogene	112
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	108
Dietary fat, bile acid metabolism and colorectal cancer	108
The complexity of p53-mediated metabolic regulation in tumor suppression	101
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics	98
An updated overview on metal nanoparticles toxicity	98
Regulation and function of SOX9 during cartilage development and regeneration	97
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer	96
Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges	94
Precision medicine in non-small cell lung cancer: Current applications and future directions	94
PROTACs: A novel strategy for cancer therapy	93
Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement	92
Artificial intelligence aids in development of nanomedicines for cancer management	91
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	90
Combining epigenetic and immune therapy to overcome cancer resistance	90
Thyroid autoimmune disorders and cancer	88
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer	87
DNMT1: A key drug target in triple-negative breast cancer	87
Antibody therapeutics and immunoregulation in cancer and autoimmune disease	87
Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement	86
The Skp2 Pathway: A Critical Target for Cancer Therapy	85
RNA methylations in human cancers	84
Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator	81
The impact of VEGF on cancer metastasis and systemic disease	81
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies	81
Tumor intrinsic and extrinsic immune functions of CD155	81
Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds	80
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches	79
Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics	79
Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature	78
The oral microbiota and its role in carcinogenesis	78
Neutrophil extracellular traps in cancer	77
Ginger and its active compounds in cancer therapy: From folk uses to nano-therapeutic applications	76
Drug repurposing for breast cancer therapy: Old weapon for new battle	74
Recent insight into the role of FBXW7 as a tumor suppressor	74
Anticancer potential of garlic and its bioactive constituents: A systematic and comprehensive review	73
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	73
Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis	70
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives	69
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy	69
NEDD4 E3 ligase: Functions and mechanism in human cancer	69
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis	69
Dissenting degradation: Deubiquitinases in cell cycle and cancer	68
EGFR signaling pathway as therapeutic target in human cancers	68
Epigenetics in hepatocellular carcinoma	68

TGF-β in developmental and fibrogenic EMTs	67
Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy	67
Colorectal cancer occurrence and treatment based on changes in intestinal flora	66
PD-L1 status in breast cancer: Current view and perspectives	66
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	66
Autophagy-modulating phytochemicals in cancer therapeutics: Current evidences and future perspectives	65
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	65
Extracellular vesicles in cancer nanomedicine	65
Circular RNAs in cancer: Limitations in functional studies and diagnostic potential	64
Predictive biomarkers for response to immune checkpoint inhibition	64
SOX4: Epigenetic regulation and role in tumorigenesis	64
At a glance: A history of autophagy and cancer	64
Functionalized mesoporous silica nanoparticles in anticancer therapeutics	62
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	62
Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy	62
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	62
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets	60
Hedgehog signaling mechanism and role in cancer	60
The potential of liquid biopsy in the management of cancer patients	60
Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis	60
The functions and regulation of Smurfs in cancers	59
Nanomedicine in treatment of breast cancer – A challenge to conventional therapy	59
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	58
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy	57
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer	56
Solid stress, competition for space and cancer: The opposing roles of mechanical cell competition in tumour initiation and growth	56
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress	56
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments	56
Determinants of response and resistance to CAR T cell therapy	56
APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis	55
Role of heparanase in tumor progression: Molecular aspects and therapeutic options	55
Tumor glycolysis, an essential sweet tooth of tumor cells	55
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer	54
Engineered nanoparticles for imaging and drug delivery in colorectal cancer	54
Repurposing of drugs as STAT3 inhibitors for cancer therapy	54
Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer	54
Role of iron in cancer	54
Cellular heterogeneity and plasticity in liver cancer	54
Role of cell surface proteoglycans in cancer immunotherapy	54
Chemokines in colon cancer progression	53
Circular RNAs as biomarkers and therapeutic targets in cancer	53
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	52
Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases	52
RBR E3 ubiquitin ligases in tumorigenesis	52
Systems biology based drug repositioning for development of cancer therapy	51
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis	51
The intricacies of NRF2 regulation in cancer	51
Mechanisms of cancer metastasis	51
miRNA dysregulation is an emerging modulator of genomic instability	51
Nanoparticle mediated cancer immunotherapy	50
AMPK signaling and its targeting in cancer progression and treatment	49
Implications of nanotechnology for the treatment of cancer: Recent advances	49
Intracellular hyaluronan: Importance for cellular functions	49
Repurposing quinacrine for treatment-refractory cancer	49
Nano-immunotherapy: Overcoming tumour immune evasion	48
Glyco-nanoparticles: New drug delivery systems in cancer therapy	48
The role of senescence in cancer development	47
Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology	47
Anticancer activity of lactic acid bacteria	47
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment	47
Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19	47
Effects of statins on brain tumors: a review	47
Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance	46
Biological functions of therapy-induced senescence in cancer	46
Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review	46
RNA-binding proteins and cancer metastasis	45
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	45
Regulatory roles for SOX11 in development, stem cells and cancer	44
Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic	44
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives	44
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine	44
Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme	44
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	44
How far have we explored fungi to fight cancer?	44
Probiotics in microbiome ecological balance providing a therapeutic window against cancer	43
Epithelial defense against cancer (EDAC)	43
Noncoding RNAs as potential mediators of resistance to cancer immunotherapy	42
Turning liabilities into opportunities: Off-target based drug repurposing in cancer	42
Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development	42
Emerging roles of long non-coding RNAs in breast cancer biology and management	42

Dysregulated FOXM1 signaling in the regulation of cancer stem cells	42
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities	41
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance	41
Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation	41
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	41
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy	40
Polyploidy formation in cancer cells: How a Trojan horse is born	40
Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective	40
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib	40
Repurposing drugs in oncology: From candidate selection to clinical adoption	39
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	39
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy	39
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer	39
Cancer stem cells in TNBC	39
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	39
Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment	39
Cullin-RING Ligase 5: Functional characterization and its role in human cancers	39
Small cell lung cancer transformation: From pathogenesis to treatment	39
Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma	39
The evolutionary legacy of immune checkpoint inhibitors	39
Epigenetic modifications of autophagy in cancer and cancer therapeutics	39
Uveal melanoma pathobiology: Metastasis to the liver	38
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	38
Interference between copper transport systems and platinum drugs	38
Genome chaos: Creating new genomic information essential for cancer macroevolution	38
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	38
The pleiotropic role of proteoglycans in extracellular vesicle mediated communication in the tumor microenvironment	38
Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?	37
Cyclin D degradation by E3 ligases in cancer progression and treatment	37
Gold nanoparticles and cancer: Detection, diagnosis and therapy	37
New Advances in Molecular Breast Cancer Pathology	37
The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance	37
Targeting NRF2 to treat cancer	37
ITCH as a potential therapeutic target in human cancers	37
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment	37
Paradoxes of cancer: Survival at the brink	37
Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies	36
MicroRNA and ER stress in cancer	36
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy	36
SOX17 in cellular reprogramming and cancer	36
Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches	36
Vimentin and cytokeratin: Good alone, bad together	36
Emerging applications of bacteria as antitumor agents	36
Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges	36
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	36
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging	36
Cancer epigenetics: Past, present and future	35
Roles of microbiota in response to cancer immunotherapy	35
Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment	35
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells	35
Vaginal microbiome and cervical cancer	35
Multiple endocrine neoplasia type 2: A review	34
Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention	34
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer	34
Clinical utility of whole-genome sequencing in precision oncology	34
Pro-survival autophagy: An emerging candidate of tumor progression through maintaining hallmarks of cancer	34
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy	34
Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update	34
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications	34
The unique immune microenvironment of liver metastases: Challenges and opportunities	33
Dietary isothiocyanates inhibit cancer progression by modulation of epigenome	33
Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy	33
Autophagy in cancer: Recent advances and future directions	33
Carcinogenic microbiota and its role in colorectal cancer development	33
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	33
Novel therapeutic strategies for spinal osteosarcomas	33
Transcription factors in SOX family: Potent regulators for cancer initiation and development in the human body	33
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors	33
Significance of human microbiome in breast cancer: Tale of an invisible and an invincible	33
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	32
Transcriptomics and solid tumors: The next frontier in precision cancer medicine	32
The two sides of Hippo pathway in cancer	32
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	32
Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model	32
Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplas	32
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	32
Proteoglycan signaling in tumor angiogenesis and endothelial cell autophagy	32
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies	32
Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: Micromanaging by not so small non-coding RNAs	32
The clinical value of detecting microcalcifications on a mammogram	32
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era	32
Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer	31
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	31
Radiation therapy-induced remodeling of the tumor immune microenvironment	31
Estrogen receptor-mediated targeting of the extracellular matrix network in cancer	31
Curcumin: A therapeutic strategy for colorectal cancer?	31
Use of DNA methylation profiling in translational oncology	31
Microbes-mediated synthesis strategies of metal nanoparticles and their potential role in cancer therapeutics	31
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment	31
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle	31
STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges	31
New approaches for targeting platinum-resistant ovarian cancer	31
Microbiota and gastric cancer	31
Current state and future perspective of drug repurposing in malignant glioma	31
HDL and cancer - causality still needs to be confirmed? Update 2020	30